ESMO 2021: COVID-19 vaccine in cancer patients is comparable to the general population

The latest findings from five studies presented at the ESMO Congress 2021 help cut short the debate on the safety and efficacy of COVID vaccines in cancer patients and re-affirm ESMO’s recommendations for early vaccination of this high-priority population, as outlined in the ESMO ten statements, which were updated in April 2021. Patients with cancer or a history of cancer were under-represented in the initial pivotal vaccine trials, despite mortality due to COVID-19 is higher in this group compared with the general population.

Read more on the ESMO website here

Share this Post!

Related post